On Monday, October 26 from 12 - 1 pm EST, please join The Worldwide Network for Innovation in Clinical Education and Research (WNICER) and The Cura Foundation for a discussion on Acute and Chronic Cardiovascular Complications of COVID-19. Our panelists are Michael E. Farkouh, MD (University of Toronto), Sascha Goonewardena, MD (University of Michigan Medical School), Peter Libby, MD (Harvard Medical School) and Robert S. Rosenson, MD (The Icahn School of Medicine at Mount Sinai). The discussion will be moderated by Max Gomez, PhD, Senior Medical Correspondent, CBS2 New York.
Max Gomez, PhD
Senior Medical Correspondent, CBS2 New York
One of TV’s most respected medical journalists, Dr. Max Gomez has produced award-winning health and science segments for network stations in New York and Philadelphia. Dr. Max has reported for “Dateline,” “The Today Show” and “48 Hours.” He is currently the senior medical correspondent for WCBS, the flagship CBS network station in New York. Over nearly four decades, he’s earned nine Emmy® Awards, three New York State Broadcasters Association awards and UPI’s Best Documentary award. Dr. Gomez has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly, and Partnership for After School Education. He co-authored three books and received an honors AB degree from Princeton University, a Ph.D. in neuroscience from the Wake Forest University School of Medicine and was U.S. National Institutes of Health postdoctoral fellow at Rockefeller University.
Michael E. Farkouh, MD
Peter Munk Chair in Multinational Clinical Trials,
Director, Heart & Stroke/Richard Lewar Centre of Excellence,
Vice-Chair, Research and Professor of Medicine, Department of Medicine
University of Toronto
Dr. Farkouh, is internationally known for his work on the management of acute coronary syndromes in the emergency room & has a special interest and expertise in the field of cardiovascular disease in diabetic patients. He graduated from the Schulich School of Medicine at Western University & completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York respectively. He holds an MSc in clinical epidemiology from McMaster University. He served as the founding director of the Mount Sinai Cardiovascular Clinical Trials Unit in New York City. Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic & was awarded the Jan J. Kellermann Memorial Award for Cardiovascular Disease Prevention from the International Academy of Cardiology. Dr. Farkouh serves as section editor for Diabetes at the Journal of the American College of Cardiology.
Sascha Goonewardena, MD
Assistant Professor of Medicine and Frances and Kenneth Eisenberg Emerging Scholar, Taubman Medical Research Institute
University of Michigan Medical School
Dr. Goonewardena received his medical degree from the University of Michigan and completed his residency in Internal Medicine at the University of Chicago. He then completed a fellowship in cardiovascular medicine at the University of Michigan, Ann Arbor, Michigan. Dr. Goonewardena is a member of the Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) and the Frances and Kenneth Eisenberg Emerging Scholar at the Taubman Medical Research Institute. Dr. Goonewardena was the recipient of an NIH K08 award from the NHLBI and has obtained received several mechanistic and translational awards focused on developing nanotechnologies for inflammatory diseases including cardiovascular disease. He was awarded the ASCI Council Young Physician-Scientist Award in 2016. Currently, he is an associate editor for Cardiovascular Drugs and Therapy and has several patents on microfluidic diagnostics and nanotherpaeutics.
Peter Libby, MD
Cardiovascular Specialist, Brigham and Women’s Hospital
and Mallinckrodt Professor of Medicine, Harvard Medical School
Dr. Libby is a cardiovascular specialist at Brigham and Women’s Hospital in Boston. His areas of clinical expertise include general & preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate laboratory studies to pilot & then large-scale clinical cardiovascular outcome trials. Dr. Libby has published extensively in top-ranked medical journals & received numerous awards and recognitions for his research accomplishments. He is an editor of Braunwald’s Heart Disease. Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine & cardiology at the Peter Bent Brigham Hospital (now BWH). He holds honorary doctorates from the Université de Lille, France & Université Laval, Québec, Canada, as well as a Doctor Medicinæ Honoris Causa from Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Robert S. Rosenson, MD
Professor of Medicine and Cardiology
The Icahn School of Medicine at Mount Sinai
Dr. Rosenson is professor of medicine at the Icahn School of Medicine at Mount Sinai, and director of cardiometabolic disorders at Mount Sinai Heart. He received his medical degree at Tulane University, residency in internal medicine at Brigham and Women’s Hospital, and fellowship in cardiovascular medicine at The University of Chicago. Dr. Rosenson is the recipient of numerous awards and honors, including the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology (2015, 2016, 2017, 2019 & 2020); The International Academy of Cardiology’s Jan J. Kellerman Memorial Award for distinguished contributions in the field of cardiovascular disease prevention (2016); and Ground-Breaking Doctors Award from Chicago magazine. He is former co-editor in chief for Cardiovascular Drugs and Therapy, section editor on metabolic disorders for the Journal of the American College of Cardiology & section editor on lipid disorders for UptoDate.
WNICER celebrates the publication of the TAILOR-PCI trial in JAMA
August 25, 2020
WNICER celebrates the publication of the TAILOR-PCI Randomized Clinical Trial results in the Journal of the American Medical Association (JAMA). The trial highlights the potential clinical impact of a personalized strategy to managing antiplatelet therapy post PCI.
We would like to congratulate and thank WNICER members Drs. Naveen L. Pereira, Michael E. Farkouh, Derek So, Verghese Mathew, Shaun G. Goodman, Mandeep Sidhu, Jean-Francois Tanguay, Yves Rosenberg and other colleagues for their tireless efforts towards advancing science.
Question: Does CYP2C19 genotype–guided prescription of oral P2Y12 inhibitor therapy after percutaneous coronary intervention (PCI) improve ischemic outcomes in patients with acute coronary syndromes and stable coronary artery disease?
Findings: In this randomized clinical trial that included 5302 patients undergoing PCI and included 1849 patients with CYP2C19 loss-of-function alleles in the primary analysis, genotype-guided selection of oral P2Y12 inhibitor therapy, compared with conventional therapy using clopidogrel, resulted in no significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, or severe recurrent ischemia at 12 months (4.0% vs 5.9%, respectively; hazard ratio, 0.66).
Meaning: Among patients with CYP2C19 loss-of-function alleles who underwent PCI, genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy, did not significantly reduce ischemic events based on the treatment effect that the study was powered to detect at 12 months.
Click here to read the full article.
Click here to read the editorial.
DR. VERGHESE MATHEW'S WNICER APPOINTMENT
Mr. John Brooks, CEO of the Worldwide Network for Innovation in Clinical Education and Research (WNICER) is pleased to announce that Dr. Verghese Mathew will assume the role of Director of the Cardiovascular Investigator Program at the WNICER effective Monday, December 16, 2019.
Dr. Mathew is a Professor of Medicine at Loyola University Chicago Stritch School of Medicine. He has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016, holding a number of leadership positions in the cardiac and vascular arenas, with joint appointments in the departments of medicine, cardiology, and radiology; he was recruited to Loyola University Medical Center in 2016 to lead the division of cardiology.
Dr. Mathew has done extensive work in the field of interventional cardiology including complex CAD, peripheral arterial interventions, and TAVR- with both basic and translational research programs. He has been an investigator in many trials that have evaluated and led to the approval of currently utilized technologies, such as coronary stents/drug eluting stents and transcatheter aortic valve replacement (TAVR); as well as phase II-IV pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions. He has published extensively in the field of interventional cardiology.
Dr. Mathew has a keen interest in integrated models of care, focusing on the appropriate application of advanced cardiovascular therapies to complex patient subsets. He continues to be an invited speaker at many national and international cardiovascular scientific conferences.
Dr. Mathew is board certified in interventional cardiology and cardiovascular diseases. He is a Fellow of the American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Interventions.